MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study.
Qing Yuan ZhangTao SunYong Mei YinHui Ping LiMin YanZhong Sheng TongChristina P OppermannYun Peng LiuRomulo CostaMan LiYing ChengQu Chang OuyangXi ChenNing LiaoXin Hong WuXiao Jia WangJi Feng FengRoberto HeggG B KanakasettyMaria A Coccia-PortugalRu Bing HanYi LuHai Dong ChiZe Fei JiangXi Chun HuPublished in: Therapeutic advances in medical oncology (2020)
The addition of abemaciclib to ET demonstrated significant and clinically meaningful improvement in PFS and ORR, without new safety signals observed in this population.Trial Registration: ClinicalTrials.gov identifier: NCT02763566.